Brief: Monopar Announces Early-Stage Trial Update For Cancer Treatment
01/06/2023 12:33
June 1 (Reuters) - Monopar Therapeutics Inc MNPR.O :
* MONOPAR ANNOUNCES ENCOURAGING CAMSIRUBICIN PHASE 1B TRIAL
UPDATE
* MONOPAR THERAPEUTICS INC - 3 OF 3 PATIENTS IN 520 MG/M(2)
COHORT
ACHIEVED STABLE DISEASE
* MONOPAR THERAPEUTICS INC - PATIENT IN 520 MG/M(2) COHORT
EXPERIENCED TUMOR SHRINKAGE AND HAD TUMOR RESECTED FOLLOWING
CAMSIRUBICIN TREATMENT
Source text for Eikon: ID:nGNX8XnGrD
Further company coverage: MNPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monopar Therapeutics
See all newsBrief: Monopar Appoints Jeffrey D. Kent, M.D., As Executive Vice President, Head Of Medical Affairs Announces Two Alxn1840 Presentations At Aasld – The Liver Meeting 2026
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Monopar Therapeutics Inc. reports results for the quarter ended June 30 - Earnings Summary
Monopar Therapeutics Inc. expected to post a loss of 62 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Alphabet, IBM, Tesla